Challenges with Target Discovery
Traditional methods for target discovery rely on preclinical models and phenotypic screens that frequently fail to predict clinical efficacy. The availability of human genetic data has surged in recent years, enabling the discovery of novel high-confidence targets. Currently, however, discovery efforts are limited by the inability to accurately predict the functional consequences (e.g. loss-of-function, neutral, gain-of-function) of genetic variants in human populations.
Genable™ is a cutting-edge platform designed to address current limitations in genomics-based target identification & prioritization through the use of massively-multiplexed experiments, human data, and machine learning. The platform uses a proprietary, integrated experimental and computational approach to confidently determine functional consequences of genetic variants observed in the population, ensuring that only the most promising targets are advanced. Genable thus provides a significant advantage over conventional target identification methods.
Increased Success Rates
Accelerated Discovery
Decreased development costs
Enhanced Association Analysis
